|
[1]
|
Baba, Y., Matsuo, H. and Schally, A.V. (1971) Structure of the Porcine LH- and FSH-Releasing Hormone. II. Confir-mation of the Proposed Structure by Conventional Sequential Analyses. Biochemical & Biophysical Research Commu-nications, 44, 459-463.
[Google Scholar] [CrossRef]
|
|
[2]
|
马小玲, 张炜. 促性腺激素释放激素类似物在妇科疾病治疗中的应用[J]. 上海医药, 2012(21): 6-8.
|
|
[3]
|
So, W.K., Cheng, J.C., Poon, S.L., et al. (2008) Gonadotropin-Releasing Hormone and Ovarian Cancer: A Functional and Mechanistic Overview. FEBS Journal, 275, 5496-5511.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Behringer, K., Breuer, K., Reineke, T., et al. (2005) Secondary Amenorrhea after Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives during Therapy: A Report from the German Hodgkin’s Lymphoma Study Group. Journal of Clinical Oncology, 23, 7555-7564.
[Google Scholar] [CrossRef]
|
|
[5]
|
Somers, E.C., Marder, W., Christman, G.M., et al. (2005) Use of a Gonadotropin-Releasing Hormone Analog for Protection against Premature Ovarian Failure during Cyclophosphamide Therapy in Women with Severe Lupus. Arthritis & Rheumatology, 52, 2761-2767.
[Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Park, I., Lee, S., Ryu, K.J., et al. (2017) A Gonadotropin-Releasing Hor-mone Agonist for the Prevention of Docetaxel-Induced Gonadal Damage. Journal of Obstetrics & Gynaecology, 37, 783-789.
[Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Moore, H., Unger, J., Phillips, K.A., Boyle, F., Hitre, E., Porter, D., Francis, P.A., Goldstein, L.J., Gomez, H.L., Vallejos, C.S., et al. (2015) Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. The New England Journal of Medicine, 372, 923-932.
[Google Scholar] [CrossRef]
|
|
[8]
|
Hulsbosch, S., Koskas, M., Tomassetti, C., et al. (2017) A Re-al-Life Analysis of Reproductive Outcome after Fertility Preservation in Female Cancer Patients. Gynecologic & Ob-stetric Investigation, 83, 156-163.
|
|
[9]
|
Leonard, R., Adamson, D., Bertelli, G., et al. (2017) GnRH Agonist for Pro-tection against Ovarian Toxicity during Chemotherapy for Early Breast Cancer: The Anglo Celtic Group OPTION Trial. Annals of Oncology, 28, 1811-1816.
|
|
[10]
|
Cima, L.N., Colita, A. and Fica, S. (2017) Perspectives on the Co-Treatment with GnRHa in Female Patients Undergoing Hematopoietic Stem Cell Transplantation. Endocrine Connections, 6, R162-R170.
[Google Scholar] [CrossRef]
|
|
[11]
|
Phelan, R., Mann, E., Napurski, C., DeFor, T.E., Petryk, A., Miller, W.P., Wagner, J.E., Verneris, M.R. and Smith, A.R. (2016) Ovarian Function after Hematopoietic Cell Transplantation: A Descriptive Study Following the Use of GnRH Agonists for Myeloablative Conditioning and Observation Only for Reduced-Intensity Conditioning. Bone Marrow Transplantation, 51, 1369-1375.
[Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Schmidt, K.T., Andersen, A.N., Greve, T., Ernst, E., Loft, A. and Andersen, C.Y. (2013) Fertility in Cancer Patients after Cryopreservation of One Ovary. Reproductive BioMedicine Online, 26, 272-279.
[Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Abdelgawad, M., Sallam, H.N. and Abousetta, A.M. (2013) Gonadatrophin Suppression to Prevent Chemotherapy-Induced Ovarian Damage. Obstetrics & Gynecology, 121, 78-86.
[Google Scholar] [CrossRef]
|
|
[14]
|
Tarlatzis, B.C. and Bili, H.N. (2003) Gonadotro-pin-Releasing Hormone Antagonists: Impact of IVF Practice and Potential Non-Assisted Reproductive Technology Applications. Current Opinion in Obstetrics & Gynecology, 15, 259-264.
[Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Motzer, R.J., Michaelson, M.D., Redman, B.G., et al. (2006) Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Plate-let-Derived Growth Factor Receptor, in Patients with Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 24, 16.
[Google Scholar] [CrossRef]
|
|
[16]
|
Blumenfeld, Z. (2011) Preservation of Ovarian Function and Minimizing Premature Ovarian Failure during Chemotherapy Using Gonadotropin-Releasing Hormone Analogs. Women’s Health, 7, 635-640.
[Google Scholar] [CrossRef]
|
|
[17]
|
Recchia, F., Saggio, G., Amiconi, G., et al. (2006) Gonadotro-pin-Releasing Hormone Analogues Added to Adjuvant Chemotherapy Protect Ovarian Function and Improve Clinical Outcomes in Young Women with Early Breast Carcinoma. Cancer, 106, 514-523.
[Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Whitehead, J., Toledo, M.G. and Stern, C.J. (2011) A Pilot Study to As-sess the Use of the Gonadotrophin Antagonist Cetrorelix in Preserving Ovarian Function during Chemotherapy. Aus-tralian & New Zealand Journal of Obstetrics & Gynaecology, 51, 452-454.
[Google Scholar] [CrossRef]
|
|
[19]
|
Digeni, A., Symeonidis, A. and Georgopoulos, N.A. (2012) Effect of the Gonadotropin-Releasing Hormone Antagonist Cetrorelix on the Prevention of Chemothera-py-Induced Ovarian Damage in Women with Hematological Malignancy. International Journal of Gynecology & Ob-stetrics, 118, 73-74.
[Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Huser, M., Smardova, L., Janku, P., et al. (2015) Fertility Status of Hodgkin Lymphoma Patients Treated with Chemotherapy and Adjuvant Gonadotro-pin-Releasing Hormone Analogues. Journal of Assisted Reproduction & Genetics, 32, 1-7.
[Google Scholar] [CrossRef] [PubMed]
|